Study identifier:BY9010/M1-602
ClinicalTrials.gov identifier:NCT00807053
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, randomized, placebo-controlled, parallel group, multicenter, dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with Seasonal Allergic Rhinitis (SAR)
Rhinitis, Allergic, Seasonal
Phase 2
No
Ciclesonide HFA, Placebo
All
480
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily | Drug: Ciclesonide HFA 75 mcg Ciclesonide HFA versus Placebo |
Active Comparator: 2 Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily | Drug: Ciclesonide HFA 150 mcg Ciclesonide HFA versus Placebo |
Active Comparator: 3 Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily | Drug: Ciclesonide HFA 300 mcg Ciclesonide HFA versus Placebo |
Placebo Comparator: 4 Placebo | Drug: Placebo Placebo |